8-K: Bioxytran Issues Preferred Stock to Insiders, Announces Research on Carbon Monoxide's Role in Brain Function

Bioxytran issued convertible preferred stock to insiders in exchange for common stock and debt, and announced a press release regarding research on carbon monoxide's impact on brain function.

Summary

• Bioxytran issued 28,971,248 shares of convertible preferred stock to company insiders.
• This issuance was in exchange for 94,057,658 shares of common stock, $353,840 in accrued salaries and other short-term debt, and the conversion of subsidiary shares.
• The preferred shares can be converted back to common stock at a 1:5 ratio and have a voting power of twice the as-if-converted basis.
• The transaction reduced the company's registered common stock to 81,850,495 shares, with 34,714,377 held at DTC.
• A press release will be issued on August 21, 2024, regarding a published article on carbon monoxide's role in mitochondrial activity and brain function.
• The article, by Avraham Mayevsky, CTO of MDX Lifesciences, highlights the use of Bioxytran's MDX Viewer in measuring the impact of oxygen on the brain.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The preferred stock issuance is a mixed bag, diluting existing shareholders but also potentially strengthening the company's financial position. The research announcement is positive, but the company's forward-looking statements are subject to risks.

Positives

• The research highlights the potential of Bioxytran's technology in understanding and treating brain-related conditions.
• The MDX Viewer is a valuable tool for quantifying the impact of oxygen on the brain and other organs.
• The study supports the development of BXT-25 for stroke, dementia, Alzheimer's, and Parkinson's disease.
• The article independently supports Bioxytran's drug development program for hypoxia and degenerative diseases.

Negatives

• The issuance of preferred stock to insiders dilutes the value of existing common stock.
• The reduction in registered common stock may impact the company's liquidity.

Risks

• The company's forward-looking statements are subject to significant risks, assumptions, and uncertainties.
• The extent of the carbohydrate structures ability to neutralize untested viruses is unknown.
• The company's actual results may differ materially from the results contemplated by forward-looking statements.

Future Outlook

The company will continue to develop its drug candidates for various diseases, including COVID-19, fibrosis, stroke, dementia, Alzheimer's, and Parkinson's disease. They will also continue to research the role of carbon monoxide in brain function.

Management Comments

• Professor Mayevsky stated that the MDX Viewer is an essential tool in quantifying the impact of oxygen on the brain and various organs.
• Professor Mayevsky also stated that the model virtually eliminates the variability from animal to animal enabling us to really measure the impact that various inputs like Carbon Monoxide to start with.

Industry Context

This announcement highlights Bioxytran's focus on developing novel treatments for neurological and viral diseases, aligning with the broader industry trend of exploring new therapeutic approaches for unmet medical needs. The use of AI and NMR imaging to design drugs is also a growing trend in the biotechnology sector.

Comparison to Industry Standards

• The use of artificial intelligence to design drugs is a growing trend, with companies like Recursion Pharmaceuticals and Exscientia also using AI for drug discovery.
• The focus on galectin targets is unique to Bioxytran, but other companies like Galecto Biotech are also exploring galectin modulation for various diseases.
• The development of BXT-25 for stroke and dementia is in line with the industry's focus on addressing neurodegenerative diseases, with companies like Biogen and Eisai also working in this area.
• The use of the MDX Viewer for real-time monitoring of tissue metabolism is a novel approach, with few direct comparables in the industry.

Related Party Transactions

• The issuance of preferred stock to company insiders is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of preferred stock.
• Employees who received preferred stock as part of the transaction may benefit.
• The research findings may positively impact patients with neurological conditions.

Next Steps

• The company will issue a press release on August 21, 2024, regarding the carbon monoxide research.
• The company will continue to develop its drug candidates for various diseases.

Key Dates

Keywords

Bioxytran, Convertible Preferred Stock, Common Stock, Carbon Monoxide, Mitochondrial Activity, Brain Function, MDX Viewer, BXT-25, Hypoxia, Degenerative Diseases, Galectin, Prolectin-M